Infection rates reported in myeloma clinical trials were high at 58% to 69% (20% to 48% ≥grade 3) but occurred later (median 46–60 d [15,19]) than those reported after anti-CD19 CAR T-cell therapy; infection density is highest between d 30 and 100 and declines beyond d 100 [4,24]. The gene discussed is CD19; the disease is infection.